World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
89
Citations
42892
World Ranking
12451
National Ranking
6377

Overview

Steven Coutre is a researcher affiliated with Stanford University in the United States. Their scholarly work primarily falls within the field of Medicine, with a strong focus on Genetics, Pathology and Forensic Medicine, Hematology, Immunology, and Oncology as subfields of study.

Coutre's research outputs emphasize several main topics:

  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Immunodeficiency and Autoimmune Disorders
  • Chronic Myeloid Leukemia Treatments
  • Advanced Breast Cancer Therapies
  • Acute Lymphoblastic Leukemia research
  • Gastrointestinal Tumor Research and Treatment

Among their recent publications are the following:

  • "Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial" (2020, The Lancet)
  • "Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia" (2022, Blood Advances)
  • "Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial" (2022, Blood)
  • "Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia" (2022, Leukemia)
  • "Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study" (2020, Clinical Cancer Research)

Frequently collaborating co-authors include:

  • Paolo Ghia
  • John C. Byrd
  • Jennifer A. Woyach
  • Paul M. Barr
  • Harry P. Erba

Steven Coutre has contributed regularly to several publication venues. Notably, their work appears most often in:

  • Blood
  • Journal of Clinical Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Advances
  • Leukemia

Best Publications

  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn

  • A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

    Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover

  • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

    Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson

  • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

    J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos

  • Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

    Jan A. Burger;Alessandra Tedeschi;Paul M. Barr;Tadeusz Robak

  • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

    Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman

  • United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia

    Steven L. Soignet;Stanley R. Frankel;Dan Douer;Martin S. Tallman

  • Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

    Jennifer A Woyach;Amy S Ruppert;Nyla A Heerema;Weiqiang Zhao

  • Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    Stephan Stilgenbauer;Barbara Eichhorst;Johannes Schetelig;Steven Coutre

  • Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Jan A. Burger

  • Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

    Tait D. Shanafelt;Xin V. Wang;Neil E. Kay;Curtis A. Hanson

  • Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

    Jennifer R. Brown;John C. Byrd;Steven E. Coutre;Don M. Benson

  • Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

    Susan O'Brien;Richard R Furman;Steven E Coutre;Jeff P Sharman

  • Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

    Jorge E Cortes;Philippe Rousselot;Dong Wook Kim;Ellen Ritchie

  • Acute myeloid leukemia, version 3.2017: Clinical practice guidelines in oncology

    Margaret R. O'Donnell;Martin S. Tallman;Camille N. Abboud;Jessica K. Altman

  • Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial

    Jeff P Sharman;Miklos Egyed;Wojciech Jurczak;Alan Skarbnik;Alan Skarbnik

  • Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.

    Bayard L. Powell;Barry Moser;Wendy Stock;Robert E. Gallagher

  • International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia

    A C Rawstron;N Villamor;M Ritgen;S Böttcher

  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

    Mark Levis;Farhad Ravandi;Eunice S. Wang;Maria R. Baer

  • Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation : the SPRINT trial

    Jeffrey McCullough;David H. Vesole;Richard J. Benjamin;Sherrill J. Slichter

Frequent Co-Authors

Susan O'Brien
Susan O'Brien University of California, Irvine
Richard R. Furman
Richard R. Furman NewYork–Presbyterian Hospital
John C. Byrd
John C. Byrd University of Pittsburgh Cancer Institute
Peter Hillmen
Peter Hillmen St James's University Hospital
Ian W. Flinn
Ian W. Flinn Sarah Cannon Research Institute
Jan A. Burger
Jan A. Burger The University of Texas MD Anderson Cancer Center
Thomas J. Kipps
Thomas J. Kipps University of California, San Diego
Jennifer R. Brown
Jennifer R. Brown Harvard University
Paolo Ghia
Paolo Ghia Vita-Salute San Raffaele University
William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in medicine doesn’t always mean committing to medical school. There are many medical billing and coding online schools that offer flexible programs, letting students quickly enter the healthcare field and work behind the scenes. For those interested in direct patient care, bridge programs like lpn to rn programs without teas test requirements can make advancing in nursing more accessible than ever.

If you’re considering a leadership path, pursuing an online healthcare management degree can be a smart move. These programs teach crucial skills in management and policy, opening doors to administrative roles in hospitals or clinics. Nurses wanting to level up can look into asn to np programs, which provide a faster route to becoming a nurse practitioner.

These online degree pathways offer flexibility, financial aid, and quicker career advancement—ideal for those passionate about healthcare but seeking alternatives to traditional medical degrees.

Best Scientists Citing Steven Coutre

Trending Scientists